“The computational analysis of the microbiome is, and will be, a major contributor to our health and well-being, both as a diagnostic and a treatment tool. Data science, which is now my major activity, has an enormous role to play in such analyses.” -Dr. Philip Bourne, PhD
SAN FRANCISCO (PRWEB) October 22, 2018
uBiome, the leader in microbial genomics, announces the addition of Dr. Philip Bourne, PhD, Director of the Data Science Institute, Stephenson Chair of Data Science, and Professor in the Department of Biomedical Engineering at UVA, to its Scientific Advisory Board. Joining the board of leading scientists and doctors from around the world, Dr. Bourne will bring to uBiome his expertise in data management and improving access to biomedical research. The appointment will help uBiome continue its advancement in human microbiome research.
“Dr. Bourne’s commitment to maximizing the value and dissemination of scientific data and knowledge aligns with uBiome’s goal of advancing the science of the microbiome and making it useful to people,” Dr. Jessica Richman, PhD, co-founder and CEO of uBiome, said. “We are honored to have him on our Scientific Advisory Board.”
Dr. Bourne served as the Associate Director for Data Science at the National Institutes of Health from 2014 to 2017 and served as the Associate Vice Chancellor for Innovation and Industry Alliances and professor in the Department of Pharmacology and Skaggs School of Pharmacy and Pharmaceutical Sciences at University of California San Diego for over 20 years. Dr. Bourne was formerly the Associate Director of the RCSB Protein Data Bank, President of the International Society for Computational Biology, and an elected fellow of the American Association for the Advancement of Science. A proponent of accessibility in biomedical research, he co-founded the open access journal PLOS Computational Biology and has published over 300 papers and 5 books himself. In addition, he co-founded 4 companies and has won several awards for his work on data-intensive computing, bioethics, and computational biology.
About joining uBiome's Scientific Advisory Board, Dr. Bourne said, “The computational analysis of the microbiome is, and will be, a major contributor to our health and well-being, both as a diagnostic and a treatment tool. Data science, which is now my major activity, has an enormous role to play in such analyses.”
In addition to Dr. Bourne, the uBiome Scientific Advisory Board also includes Dr. Joseph DeRisi (MacArthur Genius and UCSF professor), Dr. Atul Butte (head of the Institute for Computational Health Sciences at UCSF), Dr. Katherine Pollard (Director, Gladstone Institute for Data Science and Biotechnology), Dr. Joel Palefsky (UCSF School of Medicine professor), Dr. George Church (leading geneticist at Harvard University), Dr. Liz Lipski (Academic Director of Nutrition and Integrative Health Programs at Maryland University of Integrative Health), Dr. Elaine Hsiao, PhD (UCLA), and other leading scientists. The company’s Medical Advisory Board includes Dr. Alan Green (Society for Participatory Medicine), Dr. Leo Treyzon (Cedars-Sinai Medical Center), Dr. Cynthia Geyer (Medical Director of Canyon Ranch, Lenox), Dr. Robynne Chutkan (Georgetown University Hospital), Michael Docktor (Boston Children’s Hospital), Dr. Tiffany Lester (Medical Director of Parsley Health in San Francisco), Dr. Joel Kahn (Founder of of the Kahn Center for Cardiac Longevity), as well as other accomplished clinicians.
Founded in 2012, uBiome is the leader in microbial genomics. The Company’s mission is to advance the science of the microbiome and make it useful to people. uBiome combines its patented proprietary precision sequencing™ with machine learning and artificial intelligence to develop wellness products, clinical tests, and therapeutic targets.
uBiome’s commercial products include SmartGut™, the world’s first sequencing-based clinical microbiome test, which identifies microbes in the gut for patients with chronic gut conditions such as IBD, IBS, Crohn’s Disease, and ulcerative colitis; SmartJane™, the first sequencing-based women’s health screening test, which genotypes all 19 clinically relevant strains of HPV, identifies four common STDs, and surveys more than 20 vaginal microbes associated with bacterial vaginosis and other conditions; and Explorer™, a health and wellness product to understand the role that food and lifestyle can play in wellness.
uBiome’s platform has been used by hundreds of thousands of consumers, patients, and doctors and more than 200 research institutions around the world, including the US Centers for Disease Control (CDC), US National Institutes of Health (NIH), Harvard University, Stanford University, the Massachusetts Institute of Technology (MIT), University of California, San Francisco, Oxford University, and the University of Sydney.
Since its launch, the company has received widespread recognition including CNN 10: Startups to Watch, the IVY Technology Award, CNN Future 30, and was named one of Fast Company’s Most Innovative Companies in Healthcare in 2016 and in Data Science in 2018, as well as a Technology Pioneer from the World Economic Forum in 2018. For more information, visit http://www.uBiome.com.